載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$16.8637
+US$0.6637 · +4.10%
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
一般交易時段
US$16.8637
+US$0.6637 · +4.10%
盤中時間採用ET。市場資料可能有所延遲。
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
日內區間
目前US$16.8637
52週區間
目前US$16.8637
盤中時間採用ET。市場資料可能有所延遲。
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
日內區間
目前US$16.8637
52週區間
目前US$16.8637
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.27億 USD | 6.61億 USD | 5.92億 USD | 5.1億 USD | 4.84億 USD |
| 銷貨成本 | 4.45億 USD | 3.7億 USD | 3.47億 USD | 3.22億 USD | 2.97億 USD |
| 毛利 | 2.83億 USD | 2.9億 USD | 2.45億 USD | 1.88億 USD | 1.87億 USD |
| 研究與開發 | 3707.7萬 USD | 3115.9萬 USD | 2730.9萬 USD | 3032.6萬 USD | 2187.3萬 USD |
| 銷售、一般及管理費用 | 3.65億 USD | 3.1億 USD | 2.8億 USD | 2.78億 USD | 2.84億 USD |
| 營業費用 | 3.49億 USD | 3.82億 USD | 3.52億 USD | 3.46億 USD | 3.06億 USD |
| 利息收入 | 907萬 USD | 1842.7萬 USD | 1690.2萬 USD | 607.5萬 USD | 313.8萬 USD |
| 利息支出 | 375.3萬 USD | 661.7萬 USD | 690.7萬 USD | 758.1萬 USD | 822萬 USD |
| 折舊和攤銷 | 6782.4萬 USD | 7254.7萬 USD | 7258.3萬 USD | 6943萬 USD | 5335.2萬 USD |
| 營業利益 | −6607.9萬 USD | −9210.6萬 USD | −1.08億 USD | −1.58億 USD | −1.19億 USD |
| 淨利 | −1.08億 USD | −7872.6萬 USD | −8796.8萬 USD | −1.44億 USD | −834.7萬 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2003年4月16日 | 1:100 | — | — |
股票分割 | 2000年11月17日 | 4:1 | — | — |
已生效 2003年4月16日
1:100
已生效 2000年11月17日
4:1
報告持有此股票曝險的交易所交易基金。
First Trust NYSE Arca Biotechnology Index FundFBT1.05億3.61%28.91億 USD0.55%US$260.28-1.37%
Vanguard Morningstar Total Stock Market ETFVTI7425.05萬0.00%2.3兆 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM5389.49萬0.07%787.4億 USD0.19%US$277.05-0.31%
Vanguard Morningstar Small-Cap ETFVB5360.79萬0.03%1853億 USD0.03%US$288.42+0.09%
Vanguard Morningstar Small-Cap Growth ETFVBK3071.91萬0.07%447億 USD0.05%US$339.1-0.52%
Vanguard Extended Market ETFVXF2714.48萬0.03%954億 USD0.05%US$232.82-0.30%
Invesco S&P SmallCap Momentum ETFXSMO2208.11萬0.77%28.69億 USD0.35%US$81.035-0.34%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1893.23萬0.12%157.12億 USD0.03%US$53.455+0.07%First Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco S&P SmallCap Momentum ETFXSMOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
